Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646750 | 1.00 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL1742210 | 1.00 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| Hydrochloric Acid SCHEMBL16235893 | 0.98 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| Hydrochloric Acid SCHEMBL14471562 | 0.98 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL303955 | 0.86 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL303956 | 0.86 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL2612149 | 0.86 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL25256775 | 0.85 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL20783244 | 0.85 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL2393366 | 0.85 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106146612-B | A kind of glyoxalase I irreversible inhibitor and its preparation method and application | 成都大学 | 2019-09-27 | — | — | CN | claimed |
| CN-106146612-A | One class GLO-I irreversible inhibitor and its production and use | 成都大学 | 2016-11-23 | — | — | CN | claimed |
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-12-04 | — | — | US | disclosed |
| EP-4651905-A1 | NOVEL LINKERS FOR SUSTAINED DELIVERY OF THERAPEUTICS | Eli Lilly and Company (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| WO-2025235389-A1 | P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| US-12383560-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5290799-A | 7-oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1994-03-01 | — | — | US | disclosed |
| EP-0544287-A1 | Gem-dialkyl-7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1993-06-02 | — | — | EP | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0476994-A1 | 7-Oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0374952-A2 | 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | RIPK1, RIPK2, RIPK4 | CTSK 384/4885CTSS 3000/4885PPARA 4329/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CTSK 3458/4885CTSS 3560/4885PPARA 787/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CTSK 4007/4885CTSS 3820/4885PPARA 514/4885 |
| US-12383560-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | CTSK 2434/4885CTSS 2010/4885PPARA 1483/4885 |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | CTSK 1671/4885CTSS 908/4885PPARA 385/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | CTSK 1406/4885CTSS 73/4885PPARA 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.